ExcepGen is at the forefront of developing nucleic acid medicines, specifically focusing on gene therapies and vaccines that utilize advanced DNA and mRNA technologies. The company emphasizes the importance of not only improving the chemistry and delivery mechanisms of nucleic acids but also addressing the cellular responses to these therapeutics. By dampening undesirable cellular pathways, ExcepGen aims to enhance the efficacy and safety of nucleic acid-based treatments, which is crucial for the success of both preventative and therapeutic vaccines, as well as gene therapies targeting rare diseases.

The company's innovative approach is rooted in a deep understanding of biological principles, which drives their research and development efforts. ExcepGen's team of visionary scientists is dedicated to challenging existing paradigms in the field of nucleic acid therapeutics, with the goal of making significant advancements in human health. Their commitment to exploring foundational biological concepts positions them to create impactful solutions that could transform the landscape of gene therapy and vaccine development.

United States

ExcepGen is a venture-backed, early stage biotechnology company located in San Francisco. The company is focused on solving fundamental underlying problems in drug discovery and applying those solutions to create a new generation of therapeutics.

ExcepGen

Company Details